What was the “pivotal” Orilissa trial in endometriosis, and what did it show?
Orilissa (elagolix) was developed around clinical programs that studied how well it reduces endometriosis pain (especially dysmenorrhea and pelvic pain) and improves patient-reported outcomes. The pivotal evidence commonly cited for Orilissa’s efficacy comes from randomized, controlled Phase 3 trials that tested elagolix at different dose regimens and compared them with placebo, focusing on pain outcomes over the treatment period.
The Orilissa pivotal trial results supported endometriosis-pain reduction as the key clinical effect used in regulatory reviews for different dosing options.
Which outcomes were measured in the pivotal trial?
The primary endpoints in the pivotal Phase 3 program were pain-related outcomes reported by patients, including reductions in:
- Dysmenorrhea (painful menstruation)
- Non-menstrual pelvic pain
Trials also tracked durability of response over the dosing window and the proportion of patients achieving clinically meaningful pain improvement.
How do the Canadian endometriosis guidelines/labels relate to those trial results?
In Canada, the way Orilissa is used reflects what those pivotal trials demonstrated: pain reduction in endometriosis, alongside dosing and safety restrictions that match the trial populations and endpoints. Canadian prescribing information aligns clinical use with the clinical trial evidence base (and with risk controls such as those related to bone health).
What side effects were most important in the pivotal Orilissa program (and what patients in Canada ask about)?
A major theme that came out of the Orilissa development program is that the drug suppresses key reproductive hormones, which can affect:
- Bone mineral density during treatment
- Menopausal-type symptoms in some patients (for example, hot flashes)
Patients frequently ask about what happens to bone density and whether it recovers after stopping treatment, since the dosing strategies were designed to balance pain control with safety.
Why does the “Canada” search angle matter for Orilissa?
People searching “Orilissa pivotal trial endometriosis Canada” often want the Canadian-specific framing: what evidence was used for approval, and how clinicians in Canada interpret those endpoints for day-to-day treatment decisions (including which patients are good candidates and what monitoring is recommended).
If you share whether you mean “pivotal trial” for approval in Canada specifically (or a particular trial name), I can narrow to the exact study and endpoints tied to the Canadian regulatory submission.
---
Sources
[1] https://www.drugpatentwatch.com/